General Information of Drug (ID: DMTNYSF)

Drug Name
Galarubicin Drug Info
Synonyms DA-125; Metalloprotease inhibitors (cancer), Dong-A
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
114759
CAS Number
CAS 195612-80-7
TTD Drug ID
DMTNYSF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [4]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [5]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [6]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [7]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [8]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [9]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [9]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [9]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [10]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [11]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [12]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [8]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [13]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [9]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [9]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [9]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [9]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [2]
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004410)
2 Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31.
3 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
4 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
5 National Cancer Institute Drug Dictionary (drug id 747683).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
8 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
9 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
10 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
11 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
12 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
13 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.